Objective To establish and evaluate a patient-derived orthotopic xenograft ( PDOX ) model of pancreatic cancer. Methods Tissues of patient-derived pancreatic tumor were transplanted into nude mouse pancreas by surgery. The PDOX models were evaluated by the small animal near infrared fluorescence ( NIRF) optical imaging and PET/CT. The traceability of PDOX models was detected by STR technology, and the pathological changes were observed by H&E staining, immunohistochemistry, and serum level of CA19-9 was detected by ELISA. Results Apparent NIRF were observed to be accumulated in pancreatic site by optical imaging system. The location and size of the xenografts tumor were revealed by fluorescence intensity. The PET/CT images with 18F-FDG molecular probe confirmed the tumor's location and size. Ex vivo NIRF imaging of isolated organ further showed the tumor formation. The traceability of PDOX models was 99. 99% with human origin. H&E staining pathology and immunohistochemistry indicated the pancreatic cancer characteristics. The high serum level of ca19-9 confirmed the mice bearing tumor. Conclusions Pancreatic PDOX models are successfully established in this study, and it can be evaluated comprehensively by NIRF optical imaging and PET/CT, providing an appropriate platform for further research of pancreatic cancer.%目的 建立基于临床肿瘤标本的胰腺癌原位移植模型,开展模型的评价研究.方法 将临床新鲜的胰腺癌手术标本移植到裸鼠胰腺部位,建立原位异种移植模型(PDOX),通过活体成像技术和PET/CT对肿瘤生长状况进行评价;采用STR技术分析移植瘤的来源,通过组织形态观察和免疫组化判定移植瘤的病理学特征,同时检测PDOX模型外周血中CA19-9的表达水平.结果 模型建立6周后,通过活体成像观察到近红外荧光信号明显富集在肿瘤部位,通过荧光强度可以初步判断肿瘤位置和大小;使用小动物PET/CT可清晰观察到腹部18F-FDG分子探针富集区域,与预期的肿瘤位置和大小一致;安死术后,解剖分离的各个脏器组织及肿瘤组织,通过近红外荧光成像进一步确认肿瘤生长状况;STR检测证实移植瘤人源性比率为99. 99%;组织形态学和免疫组化分析表明移植肿瘤生长于裸鼠胰腺;血清中CA19-9检测进一步证实了胰腺癌的发生.结论 成功建立了人胰腺癌原位异种移植模型,通过小动物活体成像、PET/CT等技术对模型进行了全面评估,为胰腺癌的发病机制和治疗研究提供了良好的动物模型.
展开▼
